KRAS and NRAS are genes that encode GTPase proteins involved in cellular signal transduction, playing a key role in regulating processes such as cell proliferation, survival and differentiation.
Activating mutations in these genes act as true tumour drivers and currently play a decisive role in clinical practice. Their presence is associated with resistance to anti-EGFR therapies, influences patient prognostic and is essential to therapeutic stratification. For this reason, their assessment is now considered a standard of care in multiple oncological settings.
The detection of KRAS and NRAS mutations is particularly relevant in colorectal cancer, non-small cell lung cancer (NSCLC), melanoma, and pancreatic cancer.
In a context where available samples are often limited and the need for rapid results continues to increase, molecular diagnostics requires high analytical sensitivity, optimal sample utilisation and reliable, reproducible results.
At IMP Diagnostics we now offer a new technology that enables the detection of KRAS and NRAS mutations with high accuracy and a turnaround time of 24 to 48 hours.
Contact us to learn more HERE.